Inflammation in neurodegenerative diseases

Immunology

Volumn 129, Issue 2, 2010, Pages 154-169

  Amor, Sandra ^a,b   Puentes, Fabiola ^b   Baker, David ^b   Van Der Valk, Paul ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Immune response; Inflammation; Neurodegeneration; Neuroprotection; Repair

Indexed keywords

ALEMTUZUMAB; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIBIOTIC AGENT; ANTIOXIDANT; AUTACOID; BETA INTERFERON; CANNABINOID DERIVATIVE; CLADRIBINE; COMPLEMENT INHIBITOR; COPPER ZINC SUPEROXIDE DISMUTASE; CURCUMIN; CYTOKINE; FINGOLIMOD; GLATIRAMER; GLUTAMATE RECEPTOR ANTAGONIST; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MINOCYCLINE; NATALIZUMAB; NICERGOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PATTERN RECOGNITION RECEPTOR; PEPTIDE ANTIBODY; PRION PROTEIN; PRION PROTEIN ANTIBODY; RITUXIMAB; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BACTERIAL INFECTION; BRAIN DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PARKINSON DISEASE; PLASMAPHERESIS; PRION DISEASE; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRAUMATIC BRAIN INJURY; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INFLAMMATION; MICROGLIA; MODELS, ANIMAL; NEURODEGENERATIVE DISEASES; VIRUS DISEASES;

EID: 73949090103     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03225.x     Document Type: Review

References (116)

1. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009 132 : 288 295.
2. Schwartz M, London A, Shechter R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009 158 : 1133 1142.
3. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006 213 : 48 65.
4. Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol 2008 67 : 1113 1121.
5. Tian L, Rauvala H, Gahmberg CG. Neuronal regulation of immune responses in the central nervous system. Trends Immunol 2009 30 : 91 9.
6. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002 61 : 1013 1021.
7. Koedel U, Merbt UM, Schmidt C, Angele B, Popp B, Wagner H, Pfister HW, Kirschning CJ. Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses. Am J Pathol 2007 171 : 200 213.
8. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev 2009 59 : 278 292.
9. Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz-Schaeffer W, Fassbender K. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 2009 30 : 759 768.
10. Jackson AC, Rossiter JP, Lafon M. Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases. J Neurovirol 2006 12 : 229 234.
11. Lotz M, Ebert S, Esselmann H et al. Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 2005 94 : 289 298.
12. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006 129 : 3006 3019.
13. Marta M, Meier UC, Lobell A. Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev 2009 8 : 506 509.
14. Prinz M, Garbe F, Schmidt H et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006 116 : 456 464.
15. van Noort JM. Toll-like receptors as targets for inflammation, development and repair in the central nervous system. Curr Opin Investig Drugs 2007 8 : 60 5.
16. Visser L, Melief MJ, van Riel D et al. Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am J Pathol 2006 169 : 1671 1685.
17. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2009 in press.
18. Qin J, Goswami R, Dawson S, Dawson G. Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res 2008 86 : 2414 2422.
19. Sternberg Z, Weinstock-Guttman B, Hojnacki D et al. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 2008 14 : 759 763.
20. Andersson A, Covacu R, Sunnemark D et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008 84 : 1248 1255.
21. van der Putten C, Zuiderwijk-Sick EA, van Straalen L, de Geus ED, Boven LA, Kondova I, IJzerman AP, Bajramovic JJ. Differential expression of adenosine A3 receptors controls adenosine A2A receptor-mediated inhibition of TLR responses in microglia. J Immunol 2009 182 : 7603 7612.
22. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009 87 : 181 194.
23. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammtion. Mol Immunol 2007 44 : 999 1010.
24. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000 49 : 171 186.
25. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009 68 : 217 226.
26. Huizinga R, Linington C, Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol 2008 29 : 54 60.
27. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, 't Hart BA, Herrmann H, Amor S. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007 66 : 295 304.
28. Martino D, Giovannoni G. Antibasal ganglia antibodies and their relevance to movement disorders. Curr Opin Neurol 2004 17 : 425 432.
29. Rodriguez M, Warrington AE, Pease LR. Invited Article: human natural autoantibodies in the treatment of neurologic disease. Neurology 2009 72 : 1269 1276.
30. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009 22 : 201 206.
31. Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007 204 : 2899 2912.
32. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008 7 : 852 858.
33. Peferoen LAN, Lamers L, Lodder LNR et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2009 in press.
34. Huizinga R, Hintzen RQ, Assink K, van Meurs M, Amor S. T-cell responses to neurofilament light protein are part of the normal immune repertoire. Int Immunol 2009 21 : 433 441.
35. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, Ravid R. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995 375 : 798 801.
36. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 2009 17 : 91 103.
37. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, Bendotti C, Mora G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol 2009 210 : 73 9.
38. Ankeny DP, Popovich PG. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 2009 158 : 1112 1121.
39. McDole J, Johnson AJ, Pirko I. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res 2006 28 : 256 261.
40. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002 25 : 313 319. (Pubitemid 34667013)
41. Vogt J, Paul F, Aktas O et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 2009 66 : 310 322.
42. Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Sci 2008 265 : 93 6.
43. Seksenyan A, Ron-Harel N, Azoulay D et al. Thymic involution in amyotrophic lateral sclerosis. Cell Mol Med 2009 in press.
44. Nielsen HH, Ladeby R, Fenger C, Toft-Hansen H, Babcock AA, Owens T, Finsen B. Enhanced microglial clearance of myelin debris in T cell-infiltrated central nervous system. J Neuropathol Exp Neurol 2009 68 : 845 856.
45. Amor S. Virus infections of the central nervous system. In : Cook G, Zumla A, eds. Mansons' Tropical Diseases. London : Saunders Elsevier 2008 : 853 883.
46. Dalakas MC. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 1995 753 : 167 185.
47. Orvedahl A, Levine B. Autophagy and viral neurovirulence. Cell Microbiol 2008 10 : 1747 1756.
48. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 2007 55 : 483 496.
49. Zivadinov R, Zorzon M, Weinstock-Guttman B et al. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009 80 : 620 625.
50. Morgenlander JC. A syndrome of concurrent central and peripheral nervous system involvement due to Epstein-Barr virus infection. Muscle Nerve 1996 19 : 1037 1039.
51. Ito M, Baker JV, Mock DJ, Goodman AD, Blumberg BM, Shrier DA, Powers JM. Human herpesvirus 6-meningoencephalitis in an HIV patient with progressive multifocal leukoencephalopathy. Acta Neuropathol 2000 100 : 337 341.
52. Fux CA, Pfister S, Nohl F, Zimmerli S. Cytomegalovirus-associated acute transverse myelitis in immunocompetent adults. Clin Microbiol Infect 2003 9 : 1187 1190.
53. Mégret F, Prehaud C, Lafage M, Moreau P, Rouas-Freiss N, Carosella ED, Lafon M. Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. Hum Immunol 2007 68 : 294 302.
54. Liebert UG. Measles virus infections of the central nervous system. Intervirology 1997 40 : 176 184.
55. Wüthrich C, Dang X, Westmoreland S et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009 65 : 742 748.
56. Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol 2006 1 : 138 151.
57. Weber JR, Tuomanen EI. Cellular damage in bacterial meningitis: an interplay of bacterial and host driven toxicity. J Neuroimmunol 2007 184 : 45 52.
58. Van Everbroeck B, Dewulf E, Pals P, Lübke U, Martin JJ, Cras P. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging 2002 23 : 59 64.
59. Duyckaerts C, Potier M-C, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008 115 : 5 38.
60. Mineur YS, McLoughlin D, Crusio WE, Sluyter W. Genetic mouse models of AIzheimer's disease. Neural Plast 2005 12 : 299 310.
61. Harvey BK, Wang Y, Hoffer BJ. Transgenic rodent models of Parkinson's disease. Acta Neurochir Suppl 2008 101 : 89 92.
62. Meredith GE, Sonsalla P, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathol 2008 115 : 385 398.
63. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008 67 : 1149 1158.
64. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009 119 : 182 192.
65. Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+ CD25+ T cells. J Proteome Res 2009 8 : 3497 3511.
66. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005 2 : 396 409.
67. Shichita T, Sugiyama Y, Ooboshi H et al. A Pivotal role of cerebral interleukin-17-producing gammadelta T cells in the delayed phase of ischemic brain injury. Nat Med 2009 15 : 946 950.
68. Popovich PG, Hickey WF. Bone marrow chimeric rats reveal the unique distribution of resident and recruited macrophages in the contused rat spinal cord. J Neuropathol Exp Neurol 2001 60 : 676 685.
69. Hailer NP. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog Neurobiol 2008 84 : 211 233.
70. Pioro EP, Mitsumoto H. Animal models of ALS. Clin Neurosci 1996 3 : 375 385.
71. Smith RG, Engelhardt JI, Tajti J, Appel SH. Experimental immune-mediated motor neuron diseases: models for human ALS. Brain Res Bull 1993 30 : 373 380.
72. Hampton DW, Anderson J, Pryce G et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 2008 202 : 200 211.
73. Amor S, Smith PA, Hart B, Baker D. Biozzi mice: of mice and human neurological diseases. J Neuroimmunol 2005 165 : 1 10.
74. Geurts JJ, Stys PK, Minagar A, Amor S, Zivadinov R. Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009 282 : 12 20.
75. Huizinga R, Gerritsen W, Heijmans N, Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 2008 32 : 461 470.
76. Tsunoda I, Tanaka T, Saijoh Y, Fujinami RS. Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration. Am J Pathol 2007 171 : 1563 1575.
77. Fazakerley JK, Walker R. Virus demyelination. J Neurovirol 2003 9 : 148 164.
78. Aguzzi A, Wagner EF, Netzer KO, Bothe K, Anhauser I, Rethwilm A. Human foamy virus proteins accumulate in neurons and induce multinucleated giant cells in the brain of transgenic mice. Am J Pathol 1993 142 : 1061 1071.
79. Gelpi E, Preusser M, Garzuly F, Holzmann H, Heinz FX, Budka H. Visualization of Central European tick-borne encephalitis infection in fatal human cases. J Neuropathol Exp Neurol 2005 64 : 506 512.
80. Howe CL, Ure D, Adelson JD, LaFrance-Corey R, Johnson A, Rodriguez M. CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. J Neuroimmunol 2007 188 : 13 21.
81. Basile AS, Koustova E, Ioan P, Rizzoli S, Rogawski MA, Usherwood PN. IgG isolated from LP-BM5 infected mouse brain activates ionotropic glutamate receptors. Neurobiol Dis 2001 8 : 1069 1081.
82. Rall GF, Mucke L, Oldstone MB. Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo. J Exp Med 1995 182 : 1201 1212.
83. Dimcheff DE, Askovic S, Baker AH, Johnson-Fowler C, Portis JL. Endoplasmic reticulum stress is a determinant of retrovirus-induced spongiform neurodegeneration. J Virol 2003 77 : 12617 12629.
84. Zambrano A, Solis L, Salvadores N, Cortés M, Lerchundi R, Otth C. Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimers Dis 2008 14 : 259 269.
85. Ovanesov MV, Moldovan K, Smith K, Vogel MW, Pletnikov MV. Persistent Borna Disease Virus (BDV) infection activates microglia prior to a detectable loss of granule cells in the hippocampus. J Neuroinflammation 2008 5 : 16.
86. Wellmer A, Noeske C, Gerber J, Munzel U, Nau R. Spatial memory and learning deficits after experimental pneumococcal meningitis in mice. Neurosci Lett 2000 296 : 137 140.
87. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002 40 : 232 239.
88. Hermes G, Ajioka JW, Kelly KA et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation 2008 5 : 8.
89. Bauer J, Bien CG, Lassmann H. Rasmussen's encephalitis: a role for autoimmune cytotoxic T lymphocytes. Curr Opin Neurol 2002 15 : 97 200.
90. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001 9 : 809 815.
91. Mathey EK, Derfuss T, Storch MK et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007 204 : 2363 2372.
92. Derfuss T, Parikh K, Velhin S et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A 2009 106 : 8302 8307.
93. Sim RB, Kishore U, Villiers CL, Marche PN, Mitchell DA. C1q binding and complement activation by prions and amyloids. Immunobiology 2007 212 : 355 362.
94. Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol 2008 181 : 8727 8734.
95. Ramaglia V, King RH, Morgan BP, Baas F. Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol Immunol 2009 46 : 1892 1896.
96. Yamada K, Yabuki C, Seubert P et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 2009 29 : 11393 11398.
97. Zota V, Nemirovsky A, Baron R, Fisher Y, Selkoe DJ, Altmann DM, Weiner HL, Monsonego A. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 2009 183 : 3522 3530.
98. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis. 2009 34 : 63 70.
99. Alexandrenne C, Hanoux V, Dkhissi F, Boquet D, Couraud JY, Wijkhuisen A. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies. J Neuroimmunol 2009 209 : 50 6.
100. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 2007 368 : 1132 1144.
101. Blaes F. Immunotherapeutic approaches to paraneoplastic neurological disorders. Expert Opin Investig Drugs 2000 9 : 727 733.
102. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 2004 10 : 679 686.
103. Meuth SG, Kleinschnitz C, Wiendl H. Recent clinical trials and future therapies. J Neurol 2008 255 (Suppl. 6 93 6.
104. Sugaya K, Uz T, Kumar V, Manev H. New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 2000 82 : 85 94.
105. Hoozemans JJ, O'Banion MK. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005 4 : 307 315.
106. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006 13 : 1971 1978.
107. Montastruc JL, Rascol O, Senard JM. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci Biobehav Rev 1997 21 : 477 480.
108. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006 1762 : 1051 1067.
109. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 2008 33 : 2416 2426.
110. Arumugam TV, Woodruff TM, Lathia JD, Selvaraj PK, Mattson MP, Taylor SM. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009 158 : 1074 1089.
111. Leinhase I, Rozanski M, Harhausen D et al. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation 2007 4 : 13.
112. Palazuelos J, Aguado T, Pazos MR et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009 132 : 3152 3164.
113. Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 2008 93 : 120 129.
114. Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging, and neurodegeneration. J Neurosci 2009 29 : 12795 12801.
115. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, Ahmad A, Islam F. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009 19 : 636 647.
116. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida StellaAM, Galli F, Butterfield DA. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 2003 25 : 437 444.